Literature DB >> 10591286

Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist ecopipam (SCH 39166)

M K Romach1, P Glue, K Kampman, H L Kaplan, G R Somer, S Poole, L Clarke, V Coffin, J Cornish, C P O'Brien, E M Sellers.   

Abstract

BACKGROUND: The subjective and reinforcing effects of cocaine in humans are associated with the enhancement of endogenous dopamine function in the mesolimbic system. This study examined the role of dopamine D1-like receptors in the behavioral and mood effects of cocaine by evaluating the effects of the selective D1/D5 antagonist ecopipam (SCH 39166) on subjective responses to intravenous cocaine in 11 subjects with cocaine dependence as defined by DSM-IV.
METHODS: Subjects were pretreated in a randomized double-blind fashion with either placebo or 10 mg, 25 mg, or 100 mg of ecopipam orally on 4 separate occasions. Two hours later a single intravenous injection of 30 mg of cocaine was administered. Subjective and cardiovascular responses were measured and blood samples for pharmacokinetic evaluation were obtained prior to cocaine dosing and at various times after dosing.
RESULTS: The euphoric (P = .004) and stimulating (P = .03) effects of cocaine were attenuated in a dose-dependent manner by ecopipam, while ratings of desire to take cocaine were diminished (P = .02). Ecopipam in combination with cocaine was safe and well tolerated.
CONCLUSION: These data indicate a potentially important role for D1-like receptors in the acute mood-altering and rewarding effects of cocaine in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10591286     DOI: 10.1001/archpsyc.56.12.1101

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  41 in total

Review 1.  Pharmacotherapies for cocaine dependence.

Authors:  G O'Leary; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

Review 2.  Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence.

Authors:  D M Tomkins; E M Sellers
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

3.  Blockade of substantia nigra dopamine D1 receptors reduces intravenous cocaine reward in rats.

Authors:  Matthew G Quinlan; Ruth Sharf; David Y Lee; Roy A Wise; Robert Ranaldi
Journal:  Psychopharmacology (Berl)       Date:  2004-02-07       Impact factor: 4.530

Review 4.  Infecting the brain to stop addiction?

Authors:  David Nutt; Anne Lingford-Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

5.  Risperidone diminishes cocaine-induced craving.

Authors:  Richard De La Garza; Thomas F Newton; Ari D Kalechstein
Journal:  Psychopharmacology (Berl)       Date:  2004-09-25       Impact factor: 4.530

Review 6.  Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.

Authors:  Colin N Haile; James J Mahoney; Thomas F Newton; Richard De La Garza
Journal:  Pharmacol Ther       Date:  2012-01-31       Impact factor: 12.310

Review 7.  Rational development of addiction pharmacotherapies: successes, failures, and prospects.

Authors:  R Christopher Pierce; Charles P O'Brien; Paul J Kenny; Louk J M J Vanderschuren
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

8.  Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.

Authors:  Erika Pike; William W Stoops; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

9.  Repeated aripiprazole administration attenuates cocaine seeking in a rat model of relapse.

Authors:  Matthew W Feltenstein; Phong H Do; Ronald E See
Journal:  Psychopharmacology (Berl)       Date:  2009-09-25       Impact factor: 4.530

10.  c-Fos is an intracellular regulator of cocaine-induced long-term changes.

Authors:  Ming Xu
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.